JP2022509262A5 - - Google Patents
Info
- Publication number
- JP2022509262A5 JP2022509262A5 JP2021530913A JP2021530913A JP2022509262A5 JP 2022509262 A5 JP2022509262 A5 JP 2022509262A5 JP 2021530913 A JP2021530913 A JP 2021530913A JP 2021530913 A JP2021530913 A JP 2021530913A JP 2022509262 A5 JP2022509262 A5 JP 2022509262A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- composition according
- breast cancer
- abemaciclib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050208A JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773960P | 2018-11-30 | 2018-11-30 | |
| US62/773,960 | 2018-11-30 | ||
| PCT/US2019/063239 WO2020112765A1 (en) | 2018-11-30 | 2019-11-26 | Elacestrant in combination with abemaciclib in women with breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050208A Division JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509262A JP2022509262A (ja) | 2022-01-20 |
| JP2022509262A5 true JP2022509262A5 (enExample) | 2022-12-02 |
Family
ID=68966023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530913A Pending JP2022509262A (ja) | 2018-11-30 | 2019-11-26 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
| JP2025050208A Pending JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050208A Pending JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220117963A1 (enExample) |
| EP (1) | EP3886826A1 (enExample) |
| JP (2) | JP2022509262A (enExample) |
| KR (1) | KR20210097170A (enExample) |
| CN (1) | CN113164415A (enExample) |
| AU (1) | AU2019388900B2 (enExample) |
| BR (1) | BR112021010169A2 (enExample) |
| CA (1) | CA3120368A1 (enExample) |
| EA (1) | EA202191165A1 (enExample) |
| IL (1) | IL283502A (enExample) |
| JO (1) | JOP20210125A1 (enExample) |
| MA (1) | MA54293A (enExample) |
| MX (1) | MX2021005876A (enExample) |
| MY (1) | MY209833A (enExample) |
| PH (1) | PH12021551235A1 (enExample) |
| SG (1) | SG11202105455RA (enExample) |
| UA (1) | UA129403C2 (enExample) |
| WO (1) | WO2020112765A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| WO2022106711A1 (en) * | 2020-11-23 | 2022-05-27 | Sanofi | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| JP7846700B2 (ja) * | 2021-02-16 | 2026-04-15 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 |
| CN114146182A (zh) * | 2021-11-12 | 2022-03-08 | 深圳大学 | Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX384605B (es) * | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| WO2017160990A1 (en) * | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
| WO2018017410A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
-
2019
- 2019-11-26 WO PCT/US2019/063239 patent/WO2020112765A1/en not_active Ceased
- 2019-11-26 MA MA054293A patent/MA54293A/fr unknown
- 2019-11-26 SG SG11202105455RA patent/SG11202105455RA/en unknown
- 2019-11-26 JO JOP/2021/0125A patent/JOP20210125A1/ar unknown
- 2019-11-26 CN CN201980079089.6A patent/CN113164415A/zh active Pending
- 2019-11-26 EA EA202191165A patent/EA202191165A1/ru unknown
- 2019-11-26 BR BR112021010169-1A patent/BR112021010169A2/pt unknown
- 2019-11-26 EP EP19824087.1A patent/EP3886826A1/en active Pending
- 2019-11-26 MY MYPI2021002887A patent/MY209833A/en unknown
- 2019-11-26 MX MX2021005876A patent/MX2021005876A/es unknown
- 2019-11-26 UA UAA202102817A patent/UA129403C2/uk unknown
- 2019-11-26 AU AU2019388900A patent/AU2019388900B2/en active Active
- 2019-11-26 JP JP2021530913A patent/JP2022509262A/ja active Pending
- 2019-11-26 KR KR1020217020321A patent/KR20210097170A/ko not_active Ceased
- 2019-11-26 US US17/298,198 patent/US20220117963A1/en not_active Abandoned
- 2019-11-26 CA CA3120368A patent/CA3120368A1/en active Pending
-
2021
- 2021-05-27 IL IL283502A patent/IL283502A/en unknown
- 2021-05-28 PH PH12021551235A patent/PH12021551235A1/en unknown
-
2025
- 2025-03-25 JP JP2025050208A patent/JP2025094216A/ja active Pending
- 2025-05-02 US US19/197,091 patent/US20250268899A1/en not_active Abandoned
- 2025-09-24 US US19/338,117 patent/US20260014153A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| JP2012522837A5 (enExample) | ||
| JP2020516646A5 (enExample) | ||
| JP2019529581A5 (enExample) | ||
| JPWO2020111018A5 (enExample) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2017516802A5 (enExample) | ||
| RU2019133787A (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| JP2025509510A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| CN109985237A (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2016505050A5 (enExample) | ||
| JP2019535830A5 (enExample) | ||
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| JP2024512558A5 (enExample) | ||
| RU2019126627A (ru) | Схема введения доз комбинации церитиниба и молекулы антитела к pd-1 | |
| JP2025509613A5 (enExample) | ||
| JP2018522881A5 (enExample) | ||
| JP2022520859A5 (enExample) | ||
| CN118178393A (zh) | 一种act001组合物的抗肿瘤用途 | |
| RU2021115204A (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы |